Kevin Galinsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7329665/publications.pdf

Version: 2024-02-01

932766 1125271 1,204 14 10 13 citations g-index h-index papers 15 15 15 2814 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Fast Principal-Component Analysis Reveals Convergent Evolution of ADH1B in Europe and East Asia. American Journal of Human Genetics, 2016, 98, 456-472.	2.6	335
2	The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nature Genetics, 2012, 44, 1046-1050.	9.4	256
3	Sequence-based association and selection scans identify drug resistance loci in the <i>Plasmodium falciparum</i> malaria parasite. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13052-13057.	3.3	99
4	Hybrid selection for sequencing pathogen genomes from clinical samples. Genome Biology, 2011, 12, R73.	13.9	97
5	Development of a Single Nucleotide Polymorphism Barcode to Genotype Plasmodium vivax Infections. PLoS Neglected Tropical Diseases, 2015, 9, e0003539.	1.3	90
6	The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Science Translational Medicine, 2015, 7, 288ra77.	5.8	82
7	An Epigenetic Antimalarial Resistance Mechanism Involving Parasite Genes Linked to Nutrient Uptake. Journal of Biological Chemistry, 2013, 288, 19429-19440.	1.6	71
8	COIL: a methodology for evaluating malarial complexity of infection using likelihood from single nucleotide polymorphism data. Malaria Journal, 2015 , 14 , 4 .	0.8	71
9	Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. Gastroenterology, 2021, 160, 720-733.e8.	0.6	53
10	Diversity-Oriented Synthesis Probe TargetsPlasmodium falciparumCytochrome b Ubiquinone Reduction Site and Synergizes With Oxidation Site Inhibitors. Journal of Infectious Diseases, 2015, 211, 1097-1103.	1.9	29
11	Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3329-3338.	3.2	8
12	Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clinical Cancer Research, 2022, 28, 1107-1116.	3.2	7
13	Comparisons of predicted genetic modules: identification of co-expressed genes through module gene flow. Genome Informatics, 2004, 15, 221-8.	0.4	4
14	Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2022, 11, 4141.	1.0	1